I am already midway through redlining the original text, making a few changes so that the story flows more smoothly, but not really changing who-does-what-to-whom. Taking red pen to page is a laborious process, but I had hoped to finish in time to release this new version, formally called Edition 2, by the end of June.
But events have conspired to make that timeframe slip.
If it’s any consolation to those waiting for volume three (I like to think of millions of dedicated fans clamoring, although the reality is somewhat less than that) there is a good reason for the delay.
You see, my old chums in the biotech industry have drafted me back into action. They want me to help them write a convincing application to the Food and Drug Administration so they can get approval to test their new anemia treatment in human clinical trials.
For the die-hard reader, I hope your frustration at the delay is moderated by knowing my sidetracking will potentially benefit millions of people who suffer the debilitating effects of a lack of red blood cells to carry oxygen around their bodies.
I think the slowdown is worth it. How ’bout you?